Literature DB >> 20054489

Diclofenac, a Non-steroidal Anti-inflammatory Drug, Inhibits L-type Ca Channels in Neonatal Rat Ventricular Cardiomyocytes.

Oleg V Yarishkin1, Eun Mi Hwang, Donggyu Kim, Jae Cheal Yoo, Sang Soo Kang, Deok Ryoung Kim, Jae-Hee-Jung Shin, Hye-Joo Chung, Ho-Sang Jeong, Dawon Kang, Jaehee Han, Jae-Yong Park, Seong-Geun Hong.   

Abstract

A non-steroidal anti-inflammatory drug (NSAID) has many adverse effects including cardiovascular (CV) risk. Diclofenac among the nonselective NSAIDs has the highest CV risk such as congestive heart failure, which resulted commonly from the impaired cardiac pumping due to a disrupted excitation-contraction (E-C) coupling. We investigated the effects of diclofenac on the L-type calcium channels which are essential to the E-C coupling at the level of single ventricular myocytes isolated from neonatal rat heart, using the whole-cell voltage-clamp technique. Only diclofenac of three NSAIDs, including naproxen and ibuprofen, significantly reduced inward whole cell currents. At concentrations higher than 3 microM, diclofenac inhibited reversibly the Na(+) current and did irreversibly the L-type Ca(2+) channels-mediated inward current (IC(50)=12.89+/-0.43 microM) in a dose-dependent manner. However, nifedipine, a well-known L-type channel blocker, effectively inhibited the L-type Ca(2+) currents but not the Na(+) current. Our finding may explain that diclofenac causes the CV risk by the inhibition of L-type Ca(2+) channel, leading to the impairment of E-C coupling in cardiac myocytes.

Entities:  

Keywords:  Diclofenac; L-type Ca2+ current; NSAID; Rat cardiac myocytes

Year:  2009        PMID: 20054489      PMCID: PMC2802303          DOI: 10.4196/kjpp.2009.13.6.437

Source DB:  PubMed          Journal:  Korean J Physiol Pharmacol        ISSN: 1226-4512            Impact factor:   2.016


  40 in total

1.  Molecular characterization of two members of the T-type calcium channel family.

Authors:  E Perez-Reyes; J H Lee; L L Cribbs
Journal:  Ann N Y Acad Sci       Date:  1999-04-30       Impact factor: 5.691

Review 2.  The L-type calcium channel in the heart: the beat goes on.

Authors:  Ilona Bodi; Gabor Mikala; Sheryl E Koch; Shahab A Akhter; Arnold Schwartz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Open state block by fendiline of L-type Ca++ channels in ventricular myocytes from rat heart.

Authors:  H Nawrath; G Klein; J Rupp; J W Wegener; A Shainberg
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

Review 4.  Molecular characterization of a novel family of low voltage-activated, T-type, calcium channels.

Authors:  E Perez-Reyes
Journal:  J Bioenerg Biomembr       Date:  1998-08       Impact factor: 2.945

5.  "Voltage-activated Ca release" in rabbit, rat and guinea-pig cardiac myocytes, and modulation by internal cAMP.

Authors:  I A Hobai; F C Howarth; V K Pabbathi; G R Dalton; J C Hancox; J Q Zhu; S E Howlett; G R Ferrier; A J Levi
Journal:  Pflugers Arch       Date:  1997-12       Impact factor: 3.657

6.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.

Authors:  Patricia M Kearney; Colin Baigent; Jon Godwin; Heather Halls; Jonathan R Emberson; Carlo Patrono
Journal:  BMJ       Date:  2006-06-03

7.  Effects of clonixin on the electrical activity of cardiac pacemaker cells.

Authors:  M A Morales; L Inostroza; T Salazar; C Paeile
Journal:  Gen Pharmacol       Date:  1992-05

8.  Effects of flunixin and mefenamic acid on cardiac pacemaker cells. Structure-activity relationship and comparison with clonixin.

Authors:  M A Morales; T Salazar; C Paeile
Journal:  Gen Pharmacol       Date:  1993-05

9.  Quantitative analysis of the expression and distribution of calcium channel alpha 1 subunit mRNA in the atria and ventricles of the rat heart.

Authors:  Janice K Larsen; Jennifer W Mitchell; Philip M Best
Journal:  J Mol Cell Cardiol       Date:  2002-05       Impact factor: 5.000

10.  Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization.

Authors:  C R Tonussi; S H Ferreira
Journal:  Eur J Pharmacol       Date:  1994-01-14       Impact factor: 4.432

View more
  10 in total

1.  The effects of cyclooxygenase and nitric oxide synthase inhibition on oxidative stress in isolated rat heart.

Authors:  Nevena Barudzic; Drenka Turjacanin-Pantelic; Vladimir Zivkovic; Dragica Selakovic; Ivan Srejovic; Jovana Joksimovic; Jovana Jakovljevic; Dragan M Djuric; Vladimir Lj Jakovljevic
Journal:  Mol Cell Biochem       Date:  2013-06-09       Impact factor: 3.396

2.  Chronic Diclofenac Exposure Increases Mitochondrial Oxidative Stress, Inflammatory Mediators, and Cardiac Dysfunction.

Authors:  Phung N Thai; Lu Ren; Wilson Xu; James Overton; Valeriy Timofeyev; Carol E Nader; Michael Haddad; Jun Yang; Aldrin V Gomes; Bruce D Hammock; Nipavan Chiamvimonvat; Padmini Sirish
Journal:  Cardiovasc Drugs Ther       Date:  2021-09-09       Impact factor: 3.727

3.  Microphysiological heart-liver body-on-a-chip system with a skin mimic for evaluating topical drug delivery.

Authors:  Camilly P Pires de Mello; Carlos Carmona-Moran; Christopher W McAleer; Julian Perez; Elizabeth A Coln; Christopher J Long; Carlota Oleaga; Anne Riu; Reine Note; Silvia Teissier; Jessica Langer; James J Hickman
Journal:  Lab Chip       Date:  2020-01-23       Impact factor: 6.799

Review 4.  A Review of Topical Diclofenac Use in Musculoskeletal Disease.

Authors:  Bindu Nair; Regina Taylor-Gjevre
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-11

Review 5.  Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Pain-Narrative Review.

Authors:  Magdalena Kocot-Kępska; Renata Zajączkowska; Joanna Mika; David J Kopsky; Jerzy Wordliczek; Jan Dobrogowski; Anna Przeklasa-Muszyńska
Journal:  Pharmaceutics       Date:  2021-03-26       Impact factor: 6.321

6.  Emergent Temporal Signaling in Human Trabecular Meshwork Cells: Role of TRPV4-TRPM4 Interactions.

Authors:  Oleg Yarishkin; Tam T T Phuong; Felix Vazquez-Chona; Jacques Bertrand; Joseph van Battenburg-Sherwood; Sarah N Redmon; Christopher N Rudzitis; Monika Lakk; Jackson M Baumann; Marc Freichel; Eun-Mi Hwang; Darryl Overby; David Križaj
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

7.  Anti-Inflammatory and Analgesic Effects of Curcumin Nanoparticles Associated with Diclofenac Sodium in Experimental Acute Inflammation.

Authors:  Ioana Boarescu; Raluca Maria Pop; Paul-Mihai Boarescu; Ioana Corina Bocșan; Dan Gheban; Ruxandra-Mioara Râjnoveanu; Armand Râjnoveanu; Adriana Elena Bulboacă; Anca Dana Buzoianu; Sorana D Bolboacă
Journal:  Int J Mol Sci       Date:  2022-10-03       Impact factor: 6.208

8.  Diclofenac prolongs repolarization in ventricular muscle with impaired repolarization reserve.

Authors:  Attila Kristóf; Zoltán Husti; István Koncz; Zsófia Kohajda; Tamás Szél; Viktor Juhász; Péter Biliczki; Norbert Jost; István Baczkó; Julius Gy Papp; András Varró; László Virág
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

Review 9.  Diclofenac in the treatment of pain in patients with rheumatic diseases.

Authors:  Justyna Kołodziejska; Michał Kołodziejczyk
Journal:  Reumatologia       Date:  2018-06-30

10.  Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case-control study.

Authors:  Mohammad Bakhriansyah; Patrick C Souverein; Olaf H Klungel; Anthonius de Boer; Marieke T Blom; Hanno L Tan
Journal:  Europace       Date:  2019-01-01       Impact factor: 5.214

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.